Vantage Biosciences is developing a novel, oral treatment for inflammatory conditions by targeting the root drivers of inflammation. The company focuses on transforming diabetic retinopathy care.

Vantage Biosciences

Vantage Biosciences | 236 followers on LinkedIn. Transforming diabetic eye disease with an oral treatment | Vantage Biosciences is a UK-based clinical stage biotechnology company targeting the root cause of vision loss resulting from diabetes – the neuroinflammatory insult that precedes microangiopathy and leads to degeneration of the neurovascular unit of the eye. Our mission is to enable patient access to disease modifying therapy for diabetic eye disease by developing drugs that intervene at the earliest point of disease biology.

Very excited at joining the Vantage team as ClinOps VP to forge the way ahead with respect to the treatment of diabetic retinopathy.

Charmaine O'Neill

Biotech VC at ALSA Ventures

Katie Sunnucks

Clinical Project Manager at Vantage Biosciences

Steffy George

Spotlight on Vantage's Co-founder, Graeme Martin! We're thrilled to share a recent presentation by Dr Graeme Martin (PhD) on Oral Therapies for Retina at Ophthalmology Innovation Summit. Check out the presentation here: https://lnkd.in/eh8HsRXt #Ophthalmology #Innovation #VantageBiosciences #OralTherapies #Retina #OIS

We're #hiring a new Clinical Operations Manager in London, England. Apply today or share this post with your network.

Vantage Biosciences will be presenting at the upcoming Ophthalmology Innovation Source in San Diego on December 2nd, 2023. Graeme R. Martin Ph.D. will take the stage to share some exciting news regarding clinical development of VX-01, an oral therapeutic for diabetic retinopathy. This session focused on novel oral treatments for diabetic retinopathy is set to be a highlight of the Summit. Vantage is proud to be at the forefront of significant medical advances for oral treatments for diabetic eye conditions and we are excited to share our progress with the global community. Find out more: https://lnkd.in/dhSsq4MG https://ois.net/ois-xiii/ #VantageBiosciences #OpthalmologyInnovation #DiabeticRetinopathy #ClinicalInnovation #HealthcareEvents

Euro

Amazon

Microsoft Exchange Online

Office 365 Mail

GoDaddy DNS

Webflow

London Health Care Companies

Europe Biotechnology Companies with Seed Funding

Therapeutics Companies With Fewer Than 10 Employees

Europe, Middle East, and Africa (EMEA) Startups Founded in 2023

Vantage Biosciences is a developer of an oral therapy designed for diabetic eye diseases.

Seed Round - Vantage Biosciences

London

England

United Kingdom

Europe

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 13, 2024 10:45 AM	0efa5620
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 13, 2024 10:45 AM	ae07102d
crunchbase trigger	general	Nov 13, 2024 10:45 AM	d5cc7e80
crunchbase profile	general	Nov 13, 2024 8:03 PM	f9a5b498
li profile	general	Nov 13, 2024 10:45 AM	60875417
translate crunchbase fundingrounds	general	Nov 13, 2024 8:57 PM	1e2af806
peers	general	Nov 13, 2024 10:45 AM	c556b58a
news basic	general	Nov 13, 2024 10:45 AM	187dd550
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

VANT

COM:VANTAGE-BIOSCIENCES

Vantage Biosciences